Zydus Lifesciences shares in focus after USFDA issues observations
I'm PortAI, I can summarize articles.
Zydus Lifesciences shares are under scrutiny following three observations from the USFDA after an inspection at its Ankleshwar facility. The company stated there were no data-integrity issues and will address the observations promptly. Recently, Zydus launched the world's first biosimilar of Nivolumab in India. The stock closed at Rs 881.95, down 0.33%, and is currently trading 16.72% below its 52-week high of Rs 1,059.00, with a market capitalization of Rs 88,744.81 crore.
Source: Money Control The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments